Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 36569926)

  • 1. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
    Kwon S
    Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-STAT signaling pathway in non-infectious uveitis.
    Su Y; Tao T; Liu X; Su W
    Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
    Godoi MA; Camilli AC; Gonzales KGA; Costa VB; Papathanasiou E; Leite FRM; Guimarães-Stabili MR
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
    Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
    Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of JAKs in cytokine signaling and its breakdown in disease.
    Hammarén HM; Virtanen AT; Raivola J; Silvennoinen O
    Cytokine; 2019 Jun; 118():48-63. PubMed ID: 29685781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
    Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
    Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics and non-canonical aspects of JAK/STAT signalling.
    Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
    Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?
    Puigdevall L; Michiels C; Stewardson C; Dumoutier L
    J Cell Mol Med; 2022 Apr; 26(7):1865-1875. PubMed ID: 35238133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of Janus kinase trans-activation.
    Caveney NA; Saxton RA; Waghray D; Glassman CR; Tsutsumi N; Hubbard SR; Garcia KC
    Cell Rep; 2023 Mar; 42(3):112201. PubMed ID: 36867534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
    Cai B; Cai JP; Luo YL; Chen C; Zhang S
    Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.